- Research article
- Open Access
- Open Peer Review
Phenotypic alterations in breast cancer cells overexpressing the nuclear receptor co-activator AIB1
© Anzick et al; licensee BioMed Central Ltd. 2003
- Received: 17 March 2003
- Accepted: 10 September 2003
- Published: 10 September 2003
Estrogen signaling plays a critical role in a number of normal physiological processes and has important implications in the treatment of breast cancer. The p160 nuclear receptor coactivator, AIB1 (amplified in breast cancer 1), is frequently amplified and overexpressed in human breast cancer and has been shown to enhance estrogen-dependent transactivation.
To better understand the molecular and physiological consequences of AIB1 overexpression in breast cancer cells, an AIB1 cDNA was transfected into the low AIB1 expressing, estrogen-receptor (ER) negative breast cancer cell line, MDA-MB-436. The features of a derivative cell line, designated 436.1, which expresses high levels of AIB1, are described and compared with the parental cell line.
A significant increase in the levels of CREB binding protein (CBP) was observed in 436.1 cells and immunofluorescent staining revealed altered AIB1 and CBP staining patterns compared to the parental cells. Further, transient transfection assays demonstrated that the overall estrogen-dependent transactivation in 436.1 cells is approximately 20-fold higher than the parental cells and the estrogen dose-response curve is repositioned to the right. Finally, cDNA microarray analysis of approximately 7,100 cDNAs identified a number of differentially expressed genes in the 436.1 cells.
These observations lend insight into downstream signaling pathways that are influenced by AIB1.
- CREB Binding Protein
- cDNA Microarray Analysis
- Transient Transfection Assay
- P160 Coactivator
- Nuclear Receptor Coactivator
Estrogen hormone action is an essential regulator of physiologic responses ranging from reproductive development and function to bone formation and fat metabolism. Estrogens have also been considered one of the major adverse factors in the pathogenesis of breast cancer, the second leading cause of cancer-related deaths in American women [1, 2].
Estrogen action is mediated through the estrogen receptors, ER-α and ER-β, members of the nuclear hormone receptor superfamily [3, 4]. Also critical to estrogen signaling are the interactions of ER-α with transcriptional coactivators including p/CAF, CREB binding protein (CBP), p300, and the p160 family members (reviewed in ). It isthought that the coactivators activate transcription through the modification of histonesand the bridging of sequence specific transcription factors, including nuclear receptors, to the pre-initiation complex. Moreover, transcriptional activation through ER-α depends upon an ordered assembly of coactivator proteins on and off the promoter of the targetgene in a cyclic fashion [6, 7]. This selective modulation of cofactor assembly potentially contributes to the tightly regulated pattern of tissue-specific estrogen response.
The p160 coactivator, AIB1, was identified during a search for genes that are frequently amplified in human breast cancer . The frequent gene amplification and overexpression of AIB1 in ER-positive human breast cancers is hypothesized to confer a selective growth advantage through increased hormone signaling [8, 9]. While it is likely that overexpression of AIB1 contributes to tumorigenesis through this mechanism, overexpression of AIB1 has also been observed in breast tumors that are ER-negative, suggesting increased expression of AIB1 perturbs additional signaling pathways which may have important implications in the absence of ER .
In the present study, low AIB1 expressing, ER-negative breast cancer cells, MDA-MB-436, were transfected with the human AIB1 cDNA and selected for stable expression of AIB1. One of the clones expresses high levels of AIB1 message and protein and is referred to as 436.1. These cells were used to investigate estrogen receptor activity in transient transfection assays and cDNA microarray analysis was performed to identify differentially expressed genes. Here, we report the characterization of the 436.1 cell line and suggest that it may be a useful tool for examining the effects of AIB1 overexpression on a variety of signaling pathways.
The breast cancer cell line, MDA-MB-436, was obtained from the American Type Culture Collection (ATCC) and cultured in RPMI 1640 medium (Life Technologies) containing 10% fetal bovine serum. Stable transfections were performed using the standard calcium-phosphate technique using the CalPhos Maximizer System (Clontech) according to the manufacturer's recommended procedures. To generate stablytransfected lines, MDA-MB-436 cells were seeded at 1.5 × 105 cells per well into 6-well culture dishes (20 mm2) and grown overnight. Cells were transfected with 2.0 μg pcDNA3.1-AIB1 (described in ) or empty pcDNA3.1 vector (Invitrogen) and refed thefollowing day. After 48 hours, cells were transferred to 100 mm2 dishes and selected in culture medium supplemented with 500 μg/ml neomycin (G418) (Life Technologies). After approximately three weeks, neomycin-resistant colonies were isolated usingcloning rings and transferred to 12-well dishes for expansion.
RNA was extracted from exponentially growing cells using the RNeasy kit (Qiagen). Following extraction, 10–15 μg of total RNA was electrophoresed in a 1.0 % formamide/formaldehyde agarose gel and transferred by standard methods . An RNA ladder, 0.24–9.5 kb (Life Technologies), was used as a molecular size marker. Hybridization was performed using a 32P-dCTP random-primed 2.2 kb Not/SacI fragment of pCMVSPORT-B11 as probe (described in ).
For Western blot analyses, cells were harvested and lysed in RIPA buffer (1X PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing complete protease inhibitor cocktail (Boehringer Mannheim). Cellular lysates were collected after centrifugation at 10,000 × g for 15 minutes. Approximately 100 μg of total protein was denatured by boiling for three minutes in sample loading buffer (Novex) and separated by SDS-polyacrylamide gel electrophoresis. To examine proteins from transient transfection assays, a total of 3 × 10 μl of cell extract from each triplicate was pooled for Western analysis. Resolved proteins were transferred onto nylon membranes and blockedovernight at 4°C in 5% milk/PBS. AIB1 protein was detected by chemiluminescenceusing a mouse monoclonal antibody, AX15.2 . Estrogen receptor and CBP were detected using the anti-ER-α polyclonal antibody HC-20 and the anti-CBP antibody A-11 (Santa Cruz Biotechnology), respectively. Secondary antibodies used were HRP-goatanti-mouse IgG Fc specific and HRP goat anti-rabbit IgG (Jackson Immunoresearch) and detection was done using the ECL chemiluminescent substrate (Amersham) and exposing to autoradiography film (Hyperfilm-ECL, Amersham).
For fluorescent microscopy, adherent cells were grown on Falcon culture slides (Becton Dickenson) to 70% confluency. Cells were fixed with 2% paraformaldehyde, permeabolized with 1:1 methanol/acetone and blocked with 5% normal goat serum/1% casein/0.5% BSA/0.2% Triton X-100. Cells were incubated with 1:5 dilution of anti-AIB1 mAb AAP.1 hybridoma culture supernatant  and anti-CBP for 1 hour at room temperature. After washing with PBS, the cells were incubated with 2 μg/ml Rhodamine-conjugated goat anti-mouse IgG and 2 μg/ml FITC-conjugated goat anti-rabbit IgG (Jackson Immunoresearch) for 1 hour at room temperature. Following a finalwash, DAPI mounting media and coverslips were added and slides were analyzed using a fluorescent microscope (Zeiss Axiophot).
To examine the effects of estrogen, cells were transiently transfected using Lipofectamine transfection reagent (Life Technologies). The transfections were performed with 1.0 μg pGL3. luc.3ERE or pTK. luc. ERE reporter vectors, 0.4 or 10 ng of pHEGO-hyg (wild type estrogen receptor coding sequence plus hygromycin resistance, ATCC), and 5.0 ng ofpRL-tk (Renilla null luciferase reporter; Promega). The day following transfection, cells were incubated in the absence or presence of varying concentrations of 17β-estradiol or 100 nM 4-hydroxytamoxifen. Cell lysates were harvested 48 hours post transfection and reporter activities were determined using the Dual Luciferase Reporter Assay system (Promega) and the supplier's recommended methods. The pGL3. luc.3ERE, which contains three tandem copies of the ERE upstream the Simian Virus 40 promoter driving the luciferase gene, was the kind gift of Fern Merdoch (University of Wisconsin). The tk. ERE. luc, which contains three ERE upstream the thymidine kinase promoter, was giftfrom Susan Fuqua (Baylor University). The activity for subsaturating concentrations of 17β-estradiol was expressed as percent of maximal activity with saturating concentrations of 17β-estradiol (10 nM). In cases in which saturation was reached at concentrations below 10 nM 17β-estradiol, an average of the maximal activities was utilized to determine percent of maximal activity. The results are expressed in relative luciferaseactivity (Luciferase/Renilla.).
cDNA microarray preparation and analyses were performed according to standard NHGRI protocol http://www.nhgri.nih.gov/DIR/Microarray/main.html. Microarrays consisted of 7,088 known human genes. Briefly, RNA was extracted from cells using TRIzol purification (Life Technologies) followed by purification with the RNeasy kit (Qiagen). Sixty to 80 μg total RNA was fluorescently labeled with Cy5-dUTP or Cy3-dUTP (Amersham) using oligo-(dT)-primed reverse transcriptase (Superscript II, Life Technologies) and hybridized to PCR products immobilized on glass slides. Fluorescent images were acquired using a custom-designed confocal scanner equipped for dual laser excitation at the appropriate wavelengths. Pseudo-colored images were obtained by placing one fluorescent image into the green channel and the other into the red channel. A detection method was then employed to determine the actual target region based on the information from both red and green pixel values . The ratios of the red intensity to the green intensity (R/G) for all targets were determined and normalized with 88 preselected internal control genes. The hybridization quality of each target area was based on fluorescence intensity background and signal to noise ratio, as described in detail at http://www.nhgri.nih.gov/DIR/Microarray/main.html.
MDA-MB-436 cells were transfected with an expression vector containing the full-length human AIB1 cDNA and cultured in the presence of neomycin for the selection of stable transfectants. While numerous resistant colonies were selected for expansion, the majority gradually died following culture passage. The viable colonies were expanded and characterized. Additionally, five independently transfected populations were selected en masse and expanded for characterization.
Previous reports have demonstrated compensatory effects of p160 coactivator expression levels with the loss of one of the p160 coactivators [15, 16]. In SRC-1 knockout mice, for example, the expression of TIF2 is increased in certain tissues. To examine if the increase in AIB1 mRNA expression in 436.1 cells was paralleled by changes in SRC-1 or TIF2 coactivator levels, the Northern blot was stripped and hybridized with cDNAs of SRC-1 and TIF2. Densitometric measurements indicated approximately 10% and 15% reduction in the expression levels of SRC-1 and TIF2, respectively, in the 436.1 cells compared to the MDA-MB-436 parental cells or the AIB1 transfected cell line, 436.5, which failed to express the 5.7 kb transcript (Fig. 1C).
To determine if the levels of the general co-integrator proteins, CBP or p300, had changed in the 436.1 cells, the Western blot from Figure 1B was stripped and probed with either anti-CBP or anti-p300 antibodies. Interestingly, a significant increase in the levels of CBP protein was observed in the 436.1 cells compared to the parental cells, whereas levels of p300 appeared slightly reduced (Fig. 1D).
The majority (~99%) of 436.1 cells showed bright diffuse nuclear and cytoplasmic AIB1 staining, yet additional staining patterns of AIB1 were also seen in 436.1 cells that were not apparent in the parental MDA-MB-436 cells. Some of the cells displayed bright, dot-like nuclear AIB1 staining (Fig. 3C) or had reduced nuclear signal with profound cytoplasmic staining (Fig. 3D) that appeared to be concentrated in cytoplasmic organelles.
Since Western blot analysis revealed increased levels of CBP protein in the 436.1 cells, an anti-CBP antibody was used for immunofluorescent detection of endogenous CBP in each of the cell lines. Interestingly, CBP staining was faint and homogeneously diffuse throughout the nucleus in the MDA-MB-436 cells (Fig. 3A); while in the 436.1 cells, three or more bright, dot-like foci appeared in the nucleus, in addition to the diffuse nuclear staining (Fig. 3B,3C,3D). These results suggest upregulation of CBP leads to altered protein distribution within the cells. A clear correlation between the number of CBP dots and the different AIB1 staining patterns could not be established, though in a few cells some CBP dots co-localized with AIB1 dots (data not shown).
Next, we determined if the increased levels of AIB1 and CBP coactivators in 436.1 cells modified the levels of transfected ER-α. Cellular lysates from MDA-MB-436 and 436.1 cells transfected with 10 ng and 100 ng of ER-α were analyzed by Western blot. The levels of full length ER-α protein were not significantly increased in the 436.1 cells relative to the parental cells, indicating the observed increase in ER-dependenttransactivation in these cells is not the result of increased receptor levels (Fig. 5D).
Finally, cDNA microarray analysis was performed to examine endogenous gene expression  in the 436.1 cells compared to MDA-MB-436, and to identify potential downstream effects of AIB1 overexpression. Total RNAs from MDA-MB-436 and 436.1 cells were reverse-transcribed and labeled with fluorescent Cy3 and Cy5 dyes. Replicate experiments were also performed in which the fluorescent labels were reversed. Labeled RNAs were hybridized to a cDNA microarray containing 7,088 cDNAs arrayed on a glass slide. Out of 3,658 genes which met hybridization quality criteria (see methods), a total of 94 and 87 genes were upregulated and downregulated, respectively, by a factor of 3 or more in 436.1 cells compared to MDA-MB-436 cells. The 30 most significant outliers in each category are listed in Table 1 [see additional file 1].
Vast epidemiological data supports a causative role for estrogens in the development of human breast cancer. Though significant progress has been made in the identification and characterization of a large number of proteins that participate in estrogen signaling, the precise molecular mechanisms that control specific cellular responses to endogenous and exogenous ligands of the ER signaling pathway are complex and not completely understood. However, increased understanding of hormone action suggests that the cell type and/or co-regulator levels dictate the ultimate response to ligand. The present study was initiated to examine the cellular and molecular consequences of AIB1 overexpression.
Our previous report demonstrated that the majority of ER-positive breast cancer cell lines have correspondingly high levels of endogenous AIB1 expression (four out of five cell lines analyzed); therefore, the number of suitable cell lines in which to generate stable overexpression of AIB1 are limiting . Of interest, transfection of the AIB1 cDNA into the ER-positive, low AIB1-expressing cell line, T47-D, demonstrated a cell-lethal phenotype and no subclones with high levels of AIB1 expression were generated (data not shown).
Likewise, transfection of AIB1 into MDA-MB-436 breast cancer cells appears to be lethal since all but one of the surviving subclones failed to demonstrate expression of the transfected AIB1. The 436.1 line discussed in this study, however, has integrated the exogenous AIB1 cDNA and maintained high levels of AIB1 mRNA and protein expression. Most likely, 436.1 cells have acquired additional alterations which support its survival.
Though the parental MDA-MB-436 cells are ER-α negative, transient transfection of ERα was capable of inducing expression of an ERE-regulated reporter gene in the presence of estrogen, indicating these cells contain sufficient amounts of co-regulatory factors required for estrogen inducibility. Furthermore, since the levels of ER-α could be experimentally modulated in transient tranfection studies, this derivative cell line provided a useful model to compare the effects of low-level, constitutive versus high-level expression of AIB1 in the presence or absence of varying concentrations of ER-α.
Immunostaining patterns of AIB1 and CBP included diffuse fluorescent staining as well as large, bright, dot-like foci (Fig. 3). Although the punctate-staining pattern of AIB1 in 436.1 cells resembled CBP containing PML (promyelocytic leukemia protein) oncogenic domain (POD)-like structures [17, 18], the AIB1 dots appeared in only a small percentage of the population (< 2%) and typically did not overlap with CBP. Analyses of populations derived from single cell isolates revealed that the punctate staining was not a clonal variant. Similarly, Baumann et al used GFP-fused to GRIP1 to investigate its intracellular distribution in HeLa cells and observed both diffuse and focal accumulation of GRIP1 . CBP staining, on the other hand, was consistently diffuse throughout the nucleus in MDA-MB-436 cells but appeared to accumulate in PML-like bodies in the AIB1-transfected 436.1 cells. These results are consistent with observations made recently by Boisvert et al ; several cell lines do not accumulate CBP into PML bodies, but transfection of a GFP-CBP fusion protein into these cells leads to accumulation of CBP into distinct PML nuclear bodies. Taken together, these observations imply that increased amounts of AIB1 and CBP have caused the redistribution of these proteins into nuclear foci in 436.1 cells. Perhaps the levels of CBP and AIB1 are below the level required for recruitment to nuclear bodies in the non-transfected MDA-MB-436 cells. The mechanisms for upregulation of CBP in 436.1 cells remain elusive, but it will be interesting to determine if overexpression of AIB1 plays a direct role in the transcriptional regulation of CBP, or if levels of CBP are sensitized to and somehow adjusted with levels of AIB1, or vise versa.
While the overall level of reporter gene activity was dramatically increased in 436.1 cells, perhaps the most striking observation is in the right in the shift of the estrogen dose-response curve in 436.1 cells. The repositioning of the E2 dose-response curve to the right in 436.1 cells was somewhat unexpected since several studies with other receptors have demonstrated a left shift in the dose-response curve with the addition of p160 proteins, including TIF2 and SRC-1 [21–24]. However, there is no evidence that the total levels of transactivation and the position of the dose-response curve are linked. Studies with glucocorticoid [21, 25–28] and progesterone [22, 28] receptors show that the two phenomena can be totally disconnected. Increased total transactivation might be expected if the concentrations of two coactivators (AIB1 and CBP) are increased, but this does not predict the effects of these changes on the dose-response curve and EC50.
One explanation for these observations is squelching, where increased levels of AIB1 compete for some limiting factor that is crucial for nuclear receptor transactivation, such as CBP. Because we have also demonstrated that the levels of CBP are significantly elevated in the 436.1 cells it is unlikely that the level of CBP is limiting. However, AIB1 and CBP could be competing for a common factor that is now limiting due to AIB1 and CBP abundance . Also, cell specific differences, which have caused some coactivators and corepressors to be apparently inactive [21, 22] or to have opposite activities [22, 28], may be important.
Additional support for this model comes from several lines of evidence. First, convincing evidence for a limiting factor other than p160 coactivators has been demonstrated by Lopez et al. . These investigators have shown that squelching between different receptors cannot be relieved by supplying excess amounts of CBP or p160 coactivator and suggest there is an unknown factor that is necessary for receptor coactivation. Similarly, Kino et al reported that the amount of CBP that is required to see a decrease in glucocorticoid receptor (GR) transactivation is cell dependent . The presence of a limiting complex component that participates in the positioning of the dose-response curve has been established by Chen et al . Here, the effects of modulators (GR, TIF2, or a cis-acting element in the reporter gene) were additive when all components were limiting, but no further effect was obtained if saturating amounts of any one modulator was present. Second, there is a well established physical interaction between CBP/p300 and p160 coactivators [13, 30–32], and several groups have proposed that CBP and other coregulators, e.g., p160s, exist in the cytoplasm in preformed complexes [33, 34].
Candidate genes whose altered expression might contribute to the phenotypic features of the 436.1 cells, such as cell survival, multinucleated morphology, and transcriptional properties were identified by cDNA microarray technology. Comparison of RNAs from MDA-MB-436 versus 436.1 revealed a number of profound changes in the expression of genes with a variety of functions, including cell adhesion, communication, maintenance of cell shape, apoptosis, and cell cycle control. For example, cyclin D3, an important regulator of endomitosis and polyploidization in megakaryocytes , was upregulated 3.75-fold in 436.1 cells, suggesting upregulation of cyclin D3 contributed to the altered morphological features observed in these cells. An 8.2-fold upregulation of the apoptosisinhibitor 2 gene may have facilitated the survival of these cells. Downregulation of NFkB and C/EBPβ cDNAs (ratios of 0.3 and 0.5, respectively) and a number of interleukins whose gene expression are regulated by these transcription factors (Table 1) possibly indicates a shift away from NFkB and C/EBPβ signaling to transcriptional activities mediated by other transcription factors. Finally, none of the general transcription factors, including TFIIA (ratio = 1.1), TFIIB (ratio = 1.0), TFIID (ratio=.53), TFIIE (ratio = 1.25), TFIIF polypeptides 1 and 2 (ratio = 0.63, 0.94), and TFIIH (ratio = 1.16) showed increased expression in 436.1 cells, supporting the idea that AIB1 and CBP overexpression play a significant role in the observed increase in basal and E2-induced reporter gene activity in 436.1 cells. Future studies are necessary to confirm these observations and to determine which are genes regulated by transcriptional complexes containing AIB1.
In summary, we have characterized an AIB1-transfected cell line that displays high levels of AIB1 expression. The data presented here support a role for AIB1 in the estrogen-dose response and also suggest that, apart from ER-mediated pathways, AIB1 contributes to a number of signaling events which influence cell cycle, morphology, and survival. Future efforts directed at determining how overexpression of AIB1 affects cell behavior in the presence or absence of specific hormone receptors should shed light onto specific signaling pathways that are altered as a consequence of AIB1 amplification in breast cancer.
This work was done in partial fulfillment of the Ph.D. requirements of the Molecular and Cellular Oncology Program for S. L. Anzick. The authors wish to thank J. Lueders, B. Walker, K. Gayton, and H. Cunliffe for technical assistance and helpful discussions.
- McGuire WL, Chamness GC, Fuqua SA: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol. 1991, 5: 1571-1577.View ArticlePubMedGoogle Scholar
- Dickson RB, Lippman ME: Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat Res. 1988, 40: 119-165.View ArticlePubMedGoogle Scholar
- Evans RM: The steroid and thyroid hormone receptor superfamily. Science. 1988, 240: 889-895.View ArticlePubMedGoogle Scholar
- Dechering K, Boersma C, Mosselman S: Estrogen receptors alpha and beta: two receptors of a kind?. Curr Med Chem. 2000, 7: 561-576.View ArticlePubMedGoogle Scholar
- Robyr D, Wolffe AP, Wahli W: Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol. 2000, 14: 329-347. 10.1210/me.14.3.329.View ArticlePubMedGoogle Scholar
- Kraus WL, Kadonaga JT: p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev. 1998, 12: 331-342.View ArticlePubMedPubMed CentralGoogle Scholar
- Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000, 103: 843-852.View ArticlePubMedGoogle Scholar
- Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS: AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997, 277: 965-968. 10.1126/science.277.5328.965.View ArticlePubMedGoogle Scholar
- Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A, Watson PH: Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res. 2000, 60: 6266-6271.PubMedGoogle Scholar
- Bouras T, Southey MC, Venter DJ: Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Res. 2001, 61: 903-907.PubMedGoogle Scholar
- Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. 1989Google Scholar
- Azorsa DO, Meltzer PS: Production and characterization of monoclonal antibodies to the steroid receptor coactivator AIB1. Hybridoma. 1999, 18: 281-287. 10.1089/027245799315943.View ArticlePubMedGoogle Scholar
- Azorsa DO, Cunliffe HE, Meltzer PS: Association of steroid receptor coactivator AIB1 with estrogen receptor-alpha in breast cancer cells. Breast Cancer Res Treat. 2001, 70: 89-101. 10.1023/A:1012972808558.View ArticlePubMedGoogle Scholar
- Chen Y, Dougherty ER, Bittner ML: Ratio-based decisions and the quantitative analysis of cDNA microarray images. J Biomed Optics. 1997, 2: 364-374. 10.1117/1.429838.View ArticleGoogle Scholar
- Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG: Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci U S A. 2000, 97: 13549-13554. 10.1073/pnas.260463097.View ArticlePubMedPubMed CentralGoogle Scholar
- Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ, O'Malley BW: Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science. 1998, 279: 1922-1925. 10.1126/science.279.5358.1922.View ArticlePubMedGoogle Scholar
- Doucas V, Tini M, Egan DA, Evans RM: Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc Natl Acad Sci U S A. 1999, 96: 2627-2632. 10.1073/pnas.96.6.2627.View ArticlePubMedPubMed CentralGoogle Scholar
- LaMorte VJ, Dyck JA, Ochs RL, Evans RM: Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc Natl Acad Sci U S A. 1998, 95: 4991-4996. 10.1073/pnas.95.9.4991.View ArticlePubMedPubMed CentralGoogle Scholar
- Baumann CT, Ma H, Wolford R, Reyes JC, Maruvada P, Lim C, Yen PM, Stallcup MR, Hager GL: The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome. Mol Endocrinol. 2001, 15: 485-500. 10.1210/me.15.4.485.View ArticlePubMedGoogle Scholar
- Boisvert FM, Kruhlak MJ, Box AK, Hendzel MJ, Bazett-Jones DP: The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body. J Cell Biol. 2001, 152: 1099-1106. 10.1083/jcb.152.5.1099.View ArticlePubMedPubMed CentralGoogle Scholar
- Szapary D, Huang Y, Simons SS: Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol Endocrinol. 1999, 13: 2108-2121. 10.1210/me.13.12.2108.View ArticlePubMedGoogle Scholar
- Giannoukos G, Szapary D, Smith CL, Meeker JE, Simons SS: New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties. Mol Endocrinol. 2001, 15: 255-270. 10.1210/me.15.2.255.View ArticlePubMedGoogle Scholar
- Lopez GN, Webb P, Shinsako JH, Baxter JD, Greene GL, Kushner PJ: Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol Endocrinol. 1999, 13: 897-909. 10.1210/me.13.6.897.View ArticlePubMedGoogle Scholar
- Chen S, Sarlis NJ, Simons SS: Evidence for a common step in three different processes for modulating the kinetic properties of glucocorticoid receptor-induced gene transcription. J Biol Chem. 2000, 275: 30106-30117. 10.1074/jbc.M005418200.View ArticlePubMedGoogle Scholar
- Oshima H, Simons SS: Sequence-selective interactions of transcription factor elements with tandem glucocorticoid-responsive elements at physiological steroid concentrations. J Biol Chem. 1993, 268: 26858-26865.PubMedGoogle Scholar
- Szapary D, Xu M, Simons SS: Induction properties of a transiently transfected glucocorticoid-responsive gene vary with glucocorticoid receptor concentration. J Biol Chem. 1996, 271: 30576-30582. 10.1074/jbc.271.48.30576.View ArticlePubMedGoogle Scholar
- Zeng H, Plisov SY, Simons SS: Ability of the glucocorticoid modulatory element to modify glucocorticoid receptor transactivation indicates parallel pathways for the expression of glucocorticoid modulatory element and glucocorticoid response element activities. Mol Cell Endocrinol. 2000, 162: 221-234. 10.1016/S0303-7207(99)00208-7.View ArticlePubMedGoogle Scholar
- Song LN, Huse B, Rusconi S, Simons SS: Transactivation specificity of glucocorticoid versus progesterone receptors. Role of functionally different interactions of transcription factors with amino- and carboxyl-terminal receptor domains. J Biol Chem. 2001, 276: 24806-24816. 10.1074/jbc.M102610200.View ArticlePubMedGoogle Scholar
- Kino T, Nordeen SK, Chrousos GP: Conditional modulation of glucocorticoid receptor activities by CREB-binding protein (CBP) and p300. J Steroid Biochem Mol Biol. 1999, 70: 15-25. 10.1016/S0960-0760(99)00100-4.View ArticlePubMedGoogle Scholar
- Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG: The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature. 1997, 387: 677-684. 10.1038/42652.View ArticlePubMedGoogle Scholar
- Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997, 90: 569-580.View ArticlePubMedGoogle Scholar
- Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996, 85: 403-414.View ArticlePubMedGoogle Scholar
- McKenna NJ, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW: Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci U S A. 1998, 95: 11697-11702. 10.1073/pnas.95.20.11697.View ArticlePubMedPubMed CentralGoogle Scholar
- Yao TP, Ku G, Zhou N, Scully R, Livingston DM: The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci U S A. 1996, 93: 10626-10631. 10.1073/pnas.93.20.10626.View ArticlePubMedPubMed CentralGoogle Scholar
- Zimmet JM, Ladd D, Jackson CW, Stenberg PE, Ravid K: A role for cyclin D3 in the endomitotic cell cycle. Mol Cell Biol. 1997, 17: 7248-7259.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/3/22/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.